Arkolith/Insider Trading/CRNX/Form 4

Knight Jeff E.

Chief Dev. & Operating OfficerCrinetics Pharmaceuticals, Inc. (CRNX) · full profile →Form 4 · filed Apr 10, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.4M
Net Open-Market Flow
-$3.4M
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 8, 2026Option exercise(M)49K$23.98$1.2M161K
Apr 8, 2026Option exercise(M)10K$20.02$193K171K
Apr 8, 2026Option exercise(M)19K$19.64$380K190K
Apr 8, 2026Sell(S)85K$40.10$3.4M105K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 8, 2026Option exercise(M)49K—$063K
Apr 8, 2026Option exercise(M)10K—$011K
Apr 8, 2026Option exercise(M)19K—$066K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-024716) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML